Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
October 27, 2021 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 10, 2021 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further...
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
August 11, 2021 08:35 ET
|
Dyadic International, Inc.
Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the...
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent
July 27, 2021 08:20 ET
|
Dyadic International, Inc.
Arrangement includes C1 COVID-19 vaccine technology transfer and licensing agreementProvides potential funding pathway for a C1 manufactured COVID-19 vaccine to progress through Phase II and Phase III...
Dyadic’s C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal
June 28, 2021 08:30 ET
|
Dyadic International, Inc.
Dyadic’s C1-cell protein production platform selected as a fast response vaccine manufacturing model against zoonotic diseases.C1 -cell platform expressed SBV antigen exhibited efficacy, potency, and...
Dyadic announces development of COVID-19 Vaccine in India
May 26, 2021 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 26, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic to Present at Upcoming Events
May 03, 2021 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
ダイアディック･インターナショナルが炉辺談話を開催。「世界的な衛生課題の解決を支援するダイアディックの革新的なC1タンパク質技術の可能性」がテーマ
April 26, 2021 07:42 ET
|
Dyadic International, Inc.
フロリダ州ジュピター発 , April 26, 2021 (GLOBE NEWSWIRE) -- 独自のC1細胞タンパク質産生プラットフォームを開発、展開して、ワクチン、治療薬およびその他のタンパク質ベースの製品開発を最適化することを重点とするグローバルなバイオテクノロジー企業であるダイアディック･インターナショナル (Dyadic International,...
Dyadic International 舉行爐邊談話，探討「變革性 Dyadic C1 蛋白質技術在協助應對全球健康挑戰方面的潛力」
April 26, 2021 07:42 ET
|
Dyadic International, Inc.
佛羅里達州朱庇特, April 26, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc.（下稱「Dyadic」、「我們」或「公司」）(NASDAQ:DYAI) 是一家全球生物技術公司，專注於開發及部署其專有 C1 細胞蛋白質生產平台，以優化疫苗、治療藥物及其他蛋白質產品的開發。公司今天宣佈將於 2021 年 5 月 4 日（星期二）上午...
Dyadic International organise une discussion informelle sur « Le potentiel de la technologie transformatrice des protéines à cellules C1 de Dyadic pour aider à relever les défis mondiaux en matière de santé »
April 26, 2021 07:42 ET
|
Dyadic International, Inc.
JUPITER, Floride, 26 avr. 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (« Dyadic », « nous », « notre », « nos » ou la « Société ») (NASDAQ : DYAI), une société mondiale de biotechnologie...